Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 26, 2025JURNAL FARMASI DAN ILMU KEFARMASIAN INDONESIAOpen Access

A Systematic Review: Cost-Effectiveness of SGLT2 Inhibitors versus DPP-4 Inhibitors as Add-on to Metformin

View Full Paper
Ask AI
Bookmark
Share

Authors

IHIzzatu Al HanifiyahYNYunita NitaLLibriansyah

Discussion

Loading...

Member takes

Overview

Systematic review compares cost-effectiveness of metformin+SGLT2i versus metformin+DPP-4i in T2DM, suggesting SGLT2i is preferable.

Key Points

  • Combining metformin with SGLT2 inhibitors is more cost-effective for managing T2DM compared to DPP-4 inhibitors.
  • SGLT2 inhibitors improved quality of life by 0.032–0.04 QALYs and reduced hypoglycemia risks.
  • The evaluation incorporated 5 studies, all funded by the pharmaceutical industry, showing significant cost-effectiveness variation.
  • Insights based on data from the US, UK, Mexico, and Greece illustrate the benefits and initial higher costs of SGLT2 inhibitors.

Cite This Study

Hanifiyah et al. (2025) studied this question.

synapsesocial.com/papers/68d6cd5bb1249cec298b32f4https://doi.org/10.20473/jfiki.v12i22025.256-263
View Full Paper
Ask AI
Bookmark
Share